Skip to content Skip to footer
Subscribe Now
Top biosimilar news of the Apr 2025
INSIGHTS+

Key Biosimilars Events of April 2025  

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        Henlius Collaborates with Sandoz for the Commercialization of HLX13. Our team at PharmaShots…
May 6, 2025

Read more

ThoughtSpot_Evans James
THOUGHTSPOT

Revolutionizing Cold Chain Logistics: Scalable and Sustainable Ultra-Low Temperature Freezer Solutions

The pharmaceutical and biotech industries are undergoing rapid transformation, with new therapies, biologics, and vaccines driving an increasing demand for reliable ultra-low temperature storage solutions. From large-scale vaccine rollouts to personalized medicine, temperature-sensitive products are at the heart of innovation in life sciences—making dependable cold storage infrastructure not just a necessity, but a strategic asset.…
April 8, 2025

Read more

Key Biosimilars Events of March 2025
INSIGHTS+

Key Biosimilars Events of March 2025

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        Bio-Thera Collaborates with Dr. Reddy’s for the Commercialization of BAT2206 & BAT2506…
April 8, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots:At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701PThe study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701PBiocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
March 17, 2025

Read more

Key Biosimilars Events of February 2025
INSIGHTS+

Key Biosimilars Events of February 2025

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the Samsung Bioepis & Teva Partners to Commercialize…
March 4, 2025

Read more

Key Biosimilars Events of January 2025
INSIGHTS+

Key Biosimilars Events of January 2025

Shots:      Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency       Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients       A major highlight was the Samsung Bioepis & Teva Partners to Commercialize Epysqli in…
February 4, 2025

Read more

Insights+ Key Biosimilars Events of June 2024
INSIGHTS+

Insights+ Key Biosimilars Events of June 2024

Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    The major highlights were NMPA’s approval of Simcere Zaiming’s Enlituo for Treating metastatic colorectal…
July 4, 2024

Read more

Insights+ Key Biosimilars Events of January 2024
INSIGHTS+

Insights+ Key Biosimilars Events of January 2024

Shots:  Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During January, Coherus BioSciences divested its Ophthalmology Franchise that included Cimerli and Glenmark launched…
February 7, 2024

Read more

Webinar Recap Successful Drug Discovery-Collaboration Among Multiple Functions
EVENTS

Webinar Recap: Successful Drug Discovery-Collaboration Among Multiple Functions

Illuminating, informative, and engaging, our recent webinar on Successful Drug Discovery-Collaboration Among Multiple Functions with Eurofins Advinus, was an energy-packed session that highlighted the intricacies of the drug discovery process. The webinar delved deep into the nuances that are necessary for a successful drug discovery. The session was filled with stimulating case studies, highlighting crucial aspects like…
December 8, 2023

Read more

Load more